United Therapeutics Revenue 2006-2019 | UTHR

United Therapeutics revenue from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
United Therapeutics Annual Revenue
(Millions of US $)
2018 $1,628
2017 $1,725
2016 $1,599
2015 $1,466
2014 $1,289
2013 $1,117
2012 $916
2011 $743
2010 $593
2009 $359
2008 $281
2007 $211
2006 $160
2005 $116
United Therapeutics Quarterly Revenue
(Millions of US $)
Q3 2019 $402
Q2 2019 $374
Q1 2019 $363
Q4 2018 $381
Q3 2018 $413
Q2 2018 $445
Q1 2018 $389
Q4 2017 $465
Q3 2017 $446
Q2 2017 $445
Q1 2017 $371
Q4 2016 $409
Q3 2016 $408
Q2 2016 $413
Q1 2016 $369
Q4 2015 $405
Q3 2015 $386
Q2 2015 $347
Q1 2015 $328
Q4 2014 $346
Q3 2014 $330
Q2 2014 $323
Q1 2014 $289
Q4 2013 $289
Q3 2013 $302
Q2 2013 $281
Q1 2013 $245
Q4 2012 $244
Q3 2012 $242
Q2 2012 $226
Q1 2012 $204
Q4 2011 $195
Q3 2011 $202
Q2 2011 $184
Q1 2011 $163
Q4 2010 $161
Q3 2010 $169
Q2 2010 $135
Q1 2010 $129
Q4 2009 $98
Q3 2009 $97
Q2 2009 $84
Q1 2009 $80
Q4 2008 $76
Q3 2008 $75
Q2 2008 $69
Q1 2008 $62
Q4 2007 $60
Q3 2007 $59
Q2 2007 $52
Q1 2007 $40
Q4 2006 $46
Q3 2006 $40
Q2 2006 $40
Q1 2006 $33
Q4 2005 $30
Q3 2005 $33
Q2 2005 $30
Q1 2005 $23
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $4.087B $1.628B
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability. The company's product candidates include Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability in PAH patients. Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $66.758B 39.93
Takeda Pharmaceutical (TAK) Japan $62.374B 9.86
Astellas Pharma (ALPMY) Japan $32.724B 16.34
Eisai (ESALY) Japan $21.612B 41.66
Merck (MKGAF) Germany $16.401B 22.38
Grifols, S.A (GRFS) Spain $16.254B 21.30
Neurocrine Biosciences (NBIX) United States $9.639B 455.09
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
Catalent (CTLT) United States $8.907B 36.24
Jazz Pharmaceuticals (JAZZ) Ireland $8.545B 10.91
Ionis Pharmaceuticals (IONS) United States $8.458B 17.13
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.449B 0.00
IPSEN SA ADR (IPSEY) France $7.617B 0.00
STADA ARZNEIMI (STDAF) Germany $6.004B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.990B 0.00
Orion OYJ (ORINY) Finland $5.849B 30.12
Hypermarcas (HYPMY) Brazil $5.646B 17.17
Arrowhead Pharmaceuticals (ARWR) United States $5.400B 81.77
Evotec AG (EVTCY) Germany $4.191B 67.73
Sage Therapeutics (SAGE) United States $3.959B 0.00
Nektar Therapeutics (NKTR) United States $3.955B 0.00
FibroGen (FGEN) United States $3.870B 113.72
PTC Therapeutics (PTCT) United States $3.316B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.273B 12.05
ChemoCentryx (CCXI) United States $2.534B 0.00
Zogenix (ZGNX) United States $2.433B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.150B 0.00
Xencor (XNCR) United States $2.130B 64.74
Tilray (TLRY) Canada $2.108B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.976B 63.00
Heron Therapeutics (HRTX) United States $1.941B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.829B 54.10
USANA Health Sciences (USNA) United States $1.760B 18.78
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.525B 10.41
CLINIGEN GP (CLIGF) United Kingdom $1.506B 0.00
Corcept Therapeutics (CORT) United States $1.474B 17.92
Theravance Biopharma (TBPH) Cayman Islands $1.432B 0.00
Endo (ENDP) Ireland $1.370B 2.52
Enanta Pharmaceuticals (ENTA) United States $1.143B 26.10
Portola Pharmaceuticals (PTLA) United States $1.118B 0.00
Karyopharm Therapeutics (KPTI) United States $1.070B 0.00
Aerie Pharmaceuticals (AERI) United States $1.053B 0.00
Dermira (DERM) United States $1.044B 0.00
Akebia Therapeutics (AKBA) United States $0.955B 0.00
Radius Health (RDUS) United States $0.907B 0.00
Collegium Pharmaceutical (COLL) United States $0.785B 0.00
ImmunoGen (IMGN) United States $0.683B 0.00
Flexion Therapeutics (FLXN) United States $0.668B 0.00
TherapeuticsMD (TXMD) United States $0.626B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.576B 0.00
Molecular Templates (MTEM) United States $0.507B 0.00
Organogenesis Holdings (ORGO) United States $0.501B 0.00
DURECT (DRRX) United States $0.483B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.483B 0.00
Translate Bio (TBIO) United States $0.483B 0.00
Ardelyx (ARDX) United States $0.470B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.453B 0.00
Innate Pharma SA (IPHYF) France $0.438B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.429B 52.00
Siga Technologies (SIGA) United States $0.422B 9.63
BioSpecifics Technologies Corp (BSTC) United States $0.419B 18.08
Aptorum Group (APM) Hong Kong, SAR China $0.418B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.412B 0.00
Calithera Biosciences (CALA) United States $0.398B 0.00
Lannett Co Inc (LCI) United States $0.393B 4.58
Spectrum Pharmaceuticals (SPPI) United States $0.366B 0.00
Recro Pharma (REPH) United States $0.366B 0.00
Harpoon Therapeutics (HARP) United States $0.357B 0.00
OptiNose (OPTN) United States $0.356B 0.00
Indivior (INVVY) United States $0.335B 1.21
KalVista Pharmaceuticals (KALV) United States $0.331B 0.00
Rafael Holdings (RFL) United States $0.325B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.289B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.286B 0.00
MEI Pharma (MEIP) United States $0.256B 0.00
Concert Pharmaceuticals (CNCE) United States $0.248B 0.00
Concordia (CXRXF) Canada $0.248B 0.00
Jounce Therapeutics (JNCE) United States $0.241B 3.22
Ocular Therapeutix (OCUL) United States $0.223B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.210B 0.00
IMV INC (IMV) Canada $0.203B 0.00
Nature's Sunshine Products (NATR) United States $0.188B 32.43
Taiwan Liposome (TLC) Taiwan $0.170B 0.00
Xeris Pharmaceuticals (XERS) United States $0.167B 0.00
CannTrust Holdings (CTST) Canada $0.167B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.151B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.146B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.135B 0.00
Redhill Biopharma (RDHL) Israel $0.134B 0.00
CV Sciences (CVSI) United States $0.125B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.114B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.114B 0.00
Otonomy (OTIC) United States $0.110B 0.00
PolarityTE (PTE) United States $0.108B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Aquestive Therapeutics (AQST) United States $0.103B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.100B 0.00
Champions Oncology (CSBR) United States $0.098B 0.00
MediWound (MDWD) Israel $0.082B 0.00
CTI BioPharma (CTIC) United States $0.080B 0.00
Neos Therapeutics (NEOS) United States $0.080B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.077B 23.18
Aclaris Therapeutics (ACRS) United States $0.076B 0.00
Infinity Pharmaceuticals (INFI) United States $0.067B 0.00
Natural Alternatives (NAII) United States $0.066B 16.52
Entasis Therapeutics Holdings (ETTX) United States $0.064B 0.00
Nivalis Therapeutics (ALPN) United States $0.063B 0.00
SCYNEXIS (SCYX) United States $0.062B 0.00
RENEURON GP (RNUGF) United Kingdom $0.061B 0.00
Onconova Therapeutics (ONTX) United States $0.057B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.055B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.050B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.048B 0.00
Iterum Therapeutics (ITRM) Ireland $0.046B 0.00
Jaguar Animal Health (JAGX) United States $0.045B 0.00
Forward Pharma (FWP) Denmark $0.044B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.043B 0.00
ElectroCore (ECOR) United States $0.041B 0.00
Mannatechorporated (MTEX) United States $0.038B 0.00
Biomerica (BMRA) United States $0.029B 0.00
PharmAthene (ALT) United States $0.028B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.028B 0.00
Regulus Therapeutics (RGLS) United States $0.025B 0.00
China SXT Pharmaceuticals (SXTC) China $0.024B 0.00
Bio-Path Holdings (BPTH) United States $0.022B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
Cardiome Pharma (CORV) Canada $0.019B 0.00
VAXART, INC (VXRT) United States $0.018B 0.00
Shineco (TYHT) China $0.018B 0.00
Novan (NOVN) United States $0.017B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.016B 0.00
Cyanotech (CYAN) United States $0.015B 0.00
Lipocine (LPCN) United States $0.013B 0.00
Flex Pharma (SLRX) United States $0.013B 0.00
Vical (BBI) United States $0.013B 0.00
Heat Biologics (HTBX) United States $0.012B 0.00
HANCOCK JAFFE (HJLI) United States $0.011B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.010B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.009B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
RXi Pharmaceuticals (PHIO) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Midatech Pharma (MTP) United Kingdom $0.003B 0.00